Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Prazosin HCl Manufacturing Site Transfer
NCT04967443Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of prazosin in hypertension (HTN) and heart failure (HF) (5 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started Sep 2021; status: completed.
02
Drugs
prazosin
03
Conditions
hypertension (HTN)heart failure (HF)
Beyond the preview
Go deeper on NCT04967443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967443.